Can we prevent Acute Kidney Injury?

Sulfateq BV is an innovative biotechnology research company that is developing breakthrough compounds for the prevention of Acute Kidney Injury (AKI). Our compounds emerged from research on hibernation and provide a new mechanism of action for cell protection, organ protection and prophylactic use and they have a huge potential to support drug development for AKI prevention.

Find Out More

Contact

Invest

Why does Acute Kidney Injury matter?

Acute Kidney Injury is the sudden loss of kidney function and it affects more than 1.2 million people each year in the United States alone. It occurs in different situations and is particularly frequent in patients hospitalized for major surgery. Currently there is no therapy or drugs available for the protection against AKI during major surgery.



Affects 1/3 of cardiac patients



Increases hospital costs



Lengthens hospital stay



Increases readmission rate



Rises mortality for 10x

Preventing AKI by Hibernation

Sulfateq BV has conducted successful animal studies using its SUL-compounds to inhibit the occurrence of kidney injury following damage. SUL-138 is focused around AKI during invasive (heart) surgery, as successful prophylactic treatment will increase post-operative survival rate and decrease the hospitalization costs. We therefore see huge potential to address this major organ related medical need with SUL-compounds based drug development. At this moment Sulfateq is engaged in final pre-clinical development of SUL-138, i.e. safety pharmacology, while drafting proposals for Phase I and Phase II clinical studies.

U

Why hibernation?

We are inspired by the principles of hibernation. During hibernation mamals protect their body against threatening conditions. Our research has proved that hibernation can also be used for protecting cells, organs an organisms. That is why we use its natural protection process against cooling and rewarming to develop therapeutic applications.

Application

A direct application of our compounds is protecting organs and body during major surgeries. Acute Kidney Injury (AKI) can occur during various medical operations, one of which is cardiac surgery. We regard this medical need as the most direct opportunity for the application of SUL-compounds as a medical prophylactic treatment.

Investment opportunity

There is no therapy available for kidney protection, or organ protection in general, during major surgery. With our SUL-138 compound we can change this. To advance the clinical development we are seeking investors who we can offer a high-profit business model with high-potential opportunities focussing on pharmaceutical blockbuster markets.

News

Toekenning Industrial Doctorates subsidie

News

Samenwerking Sulfateq en UMCG erkent met een Industrial Doctorates subsidie Afgelopen augustus 2018 is door de Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) een Industrial Doctorate beurs toegekend aan een samenwerkingsproject...

Kidney Week 2017

News

The international kidney week is right around the corner. From 31 October until 5 November 2017 more than 13.000 kidney professionals from across the globe will come to New Orleans to exchange knowledge about the fight against kidney disease. Acute kidney injury (AKI)...

New publication SUL-121 compound

News

In the range of compounds for protecting organs from Sulfateq a new paper is published. We are proud to announce that Dr. L.E. (Leo) Deelman (UMCG) has published his paper on the protective effects of our SUL-121 compound in diabetes. SUL-121 preserves endothelial...

View All News